• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global Neurological Disorder Drugs Market Insights and Forecast to 2026

report cover
  • 30 July 2020
  • Healthcare
  • 116 Pages
  • Report Code: 24LS-15991
  • Formate :   
Download FREE Report Sample Download PDF File

Neurological Disorder Drugs -MARKET ADVISORY SERVICES

Neurological Disorder Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Neurological Disorder Drugs market is segmented into
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others

Segment by Application, the Neurological Disorder Drugs market is segmented into
Hospital
Clinic

Regional and Country-level Analysis
The Neurological Disorder Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neurological Disorder Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neurological Disorder Drugs Market Share Analysis
Neurological Disorder Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neurological Disorder Drugs business, the date to enter into the Neurological Disorder Drugs market, Neurological Disorder Drugs product introduction, recent developments, etc.

The major vendors covered:
Novartis AG
GlaxoSmithKline plc
Merck & Co.
Bayer AG
AstraZeneca
Boehringer Ingelheim GmbH
Teva Pharmaceutical
...
1 Study Coverage
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market Segments
1.3 Key Neurological Disorder Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Neurological Disorder Drugs Market Size, Estimates and Forecasts
2.1.1 Global Neurological Disorder Drugs Revenue 2015-2026
2.1.2 Global Neurological Disorder Drugs Sales 2015-2026
2.2 Global Neurological Disorder Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neurological Disorder Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neurological Disorder Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Neurological Disorder Drugs Competitor Landscape by Players
3.1 Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Neurological Disorder Drugs Sales by Manufacturers (2015-2020)
3.1.2 Neurological Disorder Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Neurological Disorder Drugs Revenue by Manufacturers
3.2.1 Neurological Disorder Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2019
3.2.5 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neurological Disorder Drugs Price by Manufacturers
3.4 Neurological Disorder Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neurological Disorder Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neurological Disorder Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Neurological Disorder Drugs Market Size by Type (2015-2020)
4.1.1 Global Neurological Disorder Drugs Sales by Type (2015-2020)
4.1.2 Global Neurological Disorder Drugs Revenue by Type (2015-2020)
4.1.3 Neurological Disorder Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neurological Disorder Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Neurological Disorder Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Neurological Disorder Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Neurological Disorder Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neurological Disorder Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Neurological Disorder Drugs Market Size by Application (2015-2020)
5.1.1 Global Neurological Disorder Drugs Sales by Application (2015-2020)
5.1.2 Global Neurological Disorder Drugs Revenue by Application (2015-2020)
5.1.3 Neurological Disorder Drugs Price by Application (2015-2020)
5.2 Neurological Disorder Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Neurological Disorder Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Neurological Disorder Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Neurological Disorder Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Neurological Disorder Drugs by Country
6.1.1 North America Neurological Disorder Drugs Sales by Country
6.1.2 North America Neurological Disorder Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neurological Disorder Drugs Market Facts & Figures by Type
6.3 North America Neurological Disorder Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Neurological Disorder Drugs by Country
7.1.1 Europe Neurological Disorder Drugs Sales by Country
7.1.2 Europe Neurological Disorder Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neurological Disorder Drugs Market Facts & Figures by Type
7.3 Europe Neurological Disorder Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Neurological Disorder Drugs by Region
8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Region
8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Type
8.3 Asia Pacific Neurological Disorder Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Neurological Disorder Drugs by Country
9.1.1 Latin America Neurological Disorder Drugs Sales by Country
9.1.2 Latin America Neurological Disorder Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neurological Disorder Drugs Market Facts & Figures by Type
9.3 Central & South America Neurological Disorder Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Neurological Disorder Drugs by Country
10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Country
10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Neurological Disorder Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Description and Business Overview
11.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline plc Neurological Disorder Drugs Products Offered
11.2.5 GlaxoSmithKline plc Related Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Description and Business Overview
11.3.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co. Neurological Disorder Drugs Products Offered
11.3.5 Merck & Co. Related Developments
11.4 Bayer AG
11.4.1 Bayer AG Corporation Information
11.4.2 Bayer AG Description and Business Overview
11.4.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer AG Neurological Disorder Drugs Products Offered
11.4.5 Bayer AG Related Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Description and Business Overview
11.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AstraZeneca Neurological Disorder Drugs Products Offered
11.5.5 AstraZeneca Related Developments
11.6 Boehringer Ingelheim GmbH
11.6.1 Boehringer Ingelheim GmbH Corporation Information
11.6.2 Boehringer Ingelheim GmbH Description and Business Overview
11.6.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim GmbH Neurological Disorder Drugs Products Offered
11.6.5 Boehringer Ingelheim GmbH Related Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Corporation Information
11.7.2 Teva Pharmaceutical Description and Business Overview
11.7.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Products Offered
11.7.5 Teva Pharmaceutical Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Neurological Disorder Drugs Products Offered
11.1.5 Novartis AG Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neurological Disorder Drugs Market Estimates and Projections by Region
12.1.1 Global Neurological Disorder Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Neurological Disorder Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.2.2 North America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neurological Disorder Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neurological Disorder Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neurological Disorder Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neurological Disorder Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neurological Disorder Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Neurological Disorder Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neurological Disorder Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables

Table 1. Neurological Disorder Drugs Market Segments

Table 2. Ranking of Global Top Neurological Disorder Drugs Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global Neurological Disorder Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)

Table 4. Major Manufacturers of Antipsychotic

Table 5. Major Manufacturers of Hypnotic & Sedative

Table 6. Major Manufacturers of Analgesics

Table 7. Major Manufacturers of Anticoagulants

Table 8. Major Manufacturers of Others

Table 9. Global Neurological Disorder Drugs Market Size Growth Rate by Application 2020-2026 (K Units)

Table 10. Global Neurological Disorder Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026

Table 11. Global Neurological Disorder Drugs Sales by Regions 2015-2020 (K Units)

Table 12. Global Neurological Disorder Drugs Sales Market Share by Regions (2015-2020)

Table 13. Global Neurological Disorder Drugs Revenue by Regions 2015-2020 (US$ Million)

Table 14. Global Neurological Disorder Drugs Sales by Manufacturers (2015-2020) (K Units)

Table 15. Global Neurological Disorder Drugs Sales Share by Manufacturers (2015-2020)

Table 16. Global Neurological Disorder Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 17. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurological Disorder Drugs as of 2019)

Table 18. Neurological Disorder Drugs Revenue by Manufacturers (2015-2020) (US$ Million)

Table 19. Neurological Disorder Drugs Revenue Share by Manufacturers (2015-2020)

Table 20. Key Manufacturers Neurological Disorder Drugs Price (2015-2020) (USD/Unit)

Table 21. Neurological Disorder Drugs Manufacturers Manufacturing Base Distribution and Headquarters

Table 22. Manufacturers Neurological Disorder Drugs Product Type

Table 23. Date of International Manufacturers Enter into Neurological Disorder Drugs Market

Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 25. Global Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 26. Global Neurological Disorder Drugs Sales Share by Type (2015-2020)

Table 27. Global Neurological Disorder Drugs Revenue by Type (2015-2020) (US$ Million)

Table 28. Global Neurological Disorder Drugs Revenue Share by Type (2015-2020)

Table 29. Neurological Disorder Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)

Table 30. Global Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 31. Global Neurological Disorder Drugs Sales Share by Application (2015-2020)

Table 32. North America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)

Table 33. North America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)

Table 34. North America Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)

Table 35. North America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)

Table 36. North America Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 37. North America Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Table 38. North America Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 39. North America Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Table 40. Europe Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)

Table 41. Europe Neurological Disorder Drugs Sales Market Share by Country (2015-2020)

Table 42. Europe Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)

Table 43. Europe Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)

Table 44. Europe Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 45. Europe Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Table 46. Europe Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 47. Europe Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Table 48. Asia Pacific Neurological Disorder Drugs Sales by Region (2015-2020) (K Units)

Table 49. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region (2015-2020)

Table 50. Asia Pacific Neurological Disorder Drugs Revenue by Region (2015-2020) (US$ Million)

Table 51. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)

Table 52. Asia Pacific Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 53. Asia Pacific Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Table 54. Asia Pacific Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 55. Asia Pacific Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Table 56. Latin America Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)

Table 57. Latin America Neurological Disorder Drugs Sales Market Share by Country (2015-2020)

Table 58. Latin Americaa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)

Table 59. Latin America Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)

Table 60. Latin America Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 61. Latin America Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Table 62. Latin America Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 63. Latin America Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Table 64. Middle East and Africa Neurological Disorder Drugs Sales by Country (2015-2020) (K Units)

Table 65. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country (2015-2020)

Table 66. Middle East and Africa Neurological Disorder Drugs Revenue by Country (2015-2020) (US$ Million)

Table 67. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country (2015-2020)

Table 68. Middle East and Africa Neurological Disorder Drugs Sales by Type (2015-2020) (K Units)

Table 69. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Table 70. Middle East and Africa Neurological Disorder Drugs Sales by Application (2015-2020) (K Units)

Table 71. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Table 72. Novartis AG Corporation Information

Table 73. Novartis AG Description and Major Businesses

Table 74. Novartis AG Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 75. Novartis AG Product

Table 76. Novartis AG Recent Development

Table 77. GlaxoSmithKline plc Corporation Information

Table 78. GlaxoSmithKline plc Description and Major Businesses

Table 79. GlaxoSmithKline plc Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 80. GlaxoSmithKline plc Product

Table 81. GlaxoSmithKline plc Recent Development

Table 82. Merck & Co. Corporation Information

Table 83. Merck & Co. Description and Major Businesses

Table 84. Merck & Co. Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 85. Merck & Co. Product

Table 86. Merck & Co. Recent Development

Table 87. Bayer AG Corporation Information

Table 88. Bayer AG Description and Major Businesses

Table 89. Bayer AG Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 90. Bayer AG Product

Table 91. Bayer AG Recent Development

Table 92. AstraZeneca Corporation Information

Table 93. AstraZeneca Description and Major Businesses

Table 94. AstraZeneca Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 95. AstraZeneca Product

Table 96. AstraZeneca Recent Development

Table 97. Boehringer Ingelheim GmbH Corporation Information

Table 98. Boehringer Ingelheim GmbH Description and Major Businesses

Table 99. Boehringer Ingelheim GmbH Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 100. Boehringer Ingelheim GmbH Product

Table 101. Boehringer Ingelheim GmbH Recent Development

Table 102. Teva Pharmaceutical Corporation Information

Table 103. Teva Pharmaceutical Description and Major Businesses

Table 104. Teva Pharmaceutical Neurological Disorder Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 105. Teva Pharmaceutical Product

Table 106. Teva Pharmaceutical Recent Development

Table 107. Global Neurological Disorder Drugs Sales Forecast by Regions (2021-2026) (K Units)

Table 108. Global Neurological Disorder Drugs Sales Market Share Forecast by Regions (2021-2026)

Table 109. Global Neurological Disorder Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)

Table 110. Global Neurological Disorder Drugs Revenue Market Share Forecast by Regions (2021-2026)

Table 111. North America: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)

Table 112. North America: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)

Table 113. Europe: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)

Table 114. Europe: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)

Table 115. Asia Pacific: Neurological Disorder Drugs Sales Forecast by Region (2021-2026) (K Units)

Table 116. Asia Pacific: Neurological Disorder Drugs Revenue Forecast by Region (2021-2026) (US$ Million)

Table 117. Latin America: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)

Table 118. Latin America: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)

Table 119. Middle East and Africa: Neurological Disorder Drugs Sales Forecast by Country (2021-2026) (K Units)

Table 120. Middle East and Africa: Neurological Disorder Drugs Revenue Forecast by Country (2021-2026) (US$ Million)

Table 121. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 122. Key Challenges

Table 123. Market Risks

Table 124. Main Points Interviewed from Key Neurological Disorder Drugs Players

Table 125. Neurological Disorder Drugs Customers List

Table 126. Neurological Disorder Drugs Distributors List

Table 127. Research Programs/Design for This Report

Table 128. Key Data Information from Secondary Sources

Table 129. Key Data Information from Primary Sources

List of Figures

Figure 1. Neurological Disorder Drugs Product Picture

Figure 2. Global Neurological Disorder Drugs Sales Market Share by Type in 2020 & 2026

Figure 3. Antipsychotic Product Picture

Figure 4. Hypnotic & Sedative Product Picture

Figure 5. Analgesics Product Picture

Figure 6. Anticoagulants Product Picture

Figure 7. Others Product Picture

Figure 8. Global Neurological Disorder Drugs Sales Market Share by Application in 2020 & 2026

Figure 9. Hospital

Figure 10. Clinic

Figure 11. Neurological Disorder Drugs Report Years Considered

Figure 12. Global Neurological Disorder Drugs Market Size 2015-2026 (US$ Million)

Figure 13. Global Neurological Disorder Drugs Sales 2015-2026 (K Units)

Figure 14. Global Neurological Disorder Drugs Market Size Market Share by Region: 2020 Versus 2026

Figure 15. Global Neurological Disorder Drugs Sales Market Share by Region (2015-2020)

Figure 16. Global Neurological Disorder Drugs Sales Market Share by Region in 2019

Figure 17. Global Neurological Disorder Drugs Revenue Market Share by Region (2015-2020)

Figure 18. Global Neurological Disorder Drugs Revenue Market Share by Region in 2019

Figure 19. Global Neurological Disorder Drugs Sales Share by Manufacturer in 2019

Figure 20. The Top 10 and 5 Players Market Share by Neurological Disorder Drugs Revenue in 2019

Figure 21. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 22. Global Neurological Disorder Drugs Sales Market Share by Type (2015-2020)

Figure 23. Global Neurological Disorder Drugs Sales Market Share by Type in 2019

Figure 24. Global Neurological Disorder Drugs Revenue Market Share by Type (2015-2020)

Figure 25. Global Neurological Disorder Drugs Revenue Market Share by Type in 2019

Figure 26. Global Neurological Disorder Drugs Market Share by Price Range (2015-2020)

Figure 27. Global Neurological Disorder Drugs Sales Market Share by Application (2015-2020)

Figure 28. Global Neurological Disorder Drugs Sales Market Share by Application in 2019

Figure 29. Global Neurological Disorder Drugs Revenue Market Share by Application (2015-2020)

Figure 30. Global Neurological Disorder Drugs Revenue Market Share by Application in 2019

Figure 31. North America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)

Figure 32. North America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 33. North America Neurological Disorder Drugs Sales Market Share by Country in 2019

Figure 34. North America Neurological Disorder Drugs Revenue Market Share by Country in 2019

Figure 35. U.S. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 36. U.S. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 37. Canada Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 38. Canada Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 39. North America Neurological Disorder Drugs Market Share by Type in 2019

Figure 40. North America Neurological Disorder Drugs Market Share by Application in 2019

Figure 41. Europe Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)

Figure 42. Europe Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 43. Europe Neurological Disorder Drugs Sales Market Share by Country in 2019

Figure 44. Europe Neurological Disorder Drugs Revenue Market Share by Country in 2019

Figure 45. Germany Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 46. Germany Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 47. France Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 48. France Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 49. U.K. Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 50. U.K. Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 51. Italy Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 52. Italy Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 53. Russia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 54. Russia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 55. Europe Neurological Disorder Drugs Market Share by Type in 2019

Figure 56. Europe Neurological Disorder Drugs Market Share by Application in 2019

Figure 57. Asia Pacific Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)

Figure 58. Asia Pacific Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 59. Asia Pacific Neurological Disorder Drugs Sales Market Share by Region in 2019

Figure 60. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Region in 2019

Figure 61. China Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 62. China Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 63. Japan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 64. Japan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 65. South Korea Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 66. South Korea Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 67. India Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 68. India Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 69. Australia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 70. Australia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 71. Taiwan Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 72. Taiwan Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 73. Indonesia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 74. Indonesia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 75. Thailand Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 76. Thailand Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 77. Malaysia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 78. Malaysia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 79. Philippines Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 80. Philippines Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 81. Vietnam Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 82. Vietnam Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 83. Asia Pacific Neurological Disorder Drugs Market Share by Type in 2019

Figure 84. Asia Pacific Neurological Disorder Drugs Market Share by Application in 2019

Figure 85. Latin America Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)

Figure 86. Latin America Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 87. Latin America Neurological Disorder Drugs Sales Market Share by Country in 2019

Figure 88. Latin America Neurological Disorder Drugs Revenue Market Share by Country in 2019

Figure 89. Mexico Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 90. Mexico Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 91. Brazil Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 92. Brazil Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 93. Argentina Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 94. Argentina Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 95. Latin America Neurological Disorder Drugs Market Share by Type in 2019

Figure 96. Latin America Neurological Disorder Drugs Market Share by Application in 2019

Figure 97. Middle East and Africa Neurological Disorder Drugs Sales Growth Rate 2015-2020 (K Units)

Figure 98. Middle East and Africa Neurological Disorder Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 99. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Country in 2019

Figure 100. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Country in 2019

Figure 101. Turkey Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 102. Turkey Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 103. Saudi Arabia Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 104. Saudi Arabia Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 105. U.A.E Neurological Disorder Drugs Sales Growth Rate (2015-2020) (K Units)

Figure 106. U.A.E Neurological Disorder Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 107. Middle East and Africa Neurological Disorder Drugs Market Share by Type in 2019

Figure 108. Middle East and Africa Neurological Disorder Drugs Market Share by Application in 2019

Figure 109. North America Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 110. North America Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 111. Europe Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 112. Europe Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 113. Asia Pacific Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 114. Asia Pacific Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 115. Latin America Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 116. Latin America Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 117. Middle East and Africa Neurological Disorder Drugs Sales Growth Rate Forecast (2021-2026) (K Units)

Figure 118. Middle East and Africa Neurological Disorder Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 119. Porter's Five Forces Analysis

Figure 120. Channels of Distribution

Figure 121. Distributors Profiles

Figure 122. Bottom-up and Top-down Approaches for This Report

Figure 123. Data Triangulation

Figure 124. Key Executives Interviewed

Novartis AG

GlaxoSmithKline plc

Merck & Co.

Bayer AG

AstraZeneca

Boehringer Ingelheim GmbH

Teva Pharmaceutical

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3120

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase